Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Niraparib Administered Alone and in Combination With PD-1 Inhibitor in Patients With Non-Small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03308942
Recruitment Status : Active, not recruiting
First Posted : October 13, 2017
Last Update Posted : October 28, 2019
Sponsor:
Collaborators:
Covance
Myriad Genetics, Inc.
NeoGenomics Laboratories
DrugDev
Resolution Bioscience
Syneos Health
Almac Group
imedidata
Information provided by (Responsible Party):
Tesaro, Inc.

Brief Summary:
A phase 2 study to evaluate the efficacy of niraparib alone and in combination with PD-1 inhibitor in three cohorts: all histologies with high PD-L1 expression (greater than 50% TPS), all histologies low PD-L1 expression (1-49% TPS), and squamous cell lung cancer. [TPS=Tumor Proportion Score]

Condition or disease Intervention/treatment Phase
Lung Neoplasms Drug: Niraparib Biological: PD-1 Inhibitor Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 142 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 2, Multi-Arm Study of Niraparib Administered Alone and in Combination With PD-1 Inhibitor in Patients With Non-Small Cell Lung Cancer
Actual Study Start Date : November 14, 2017
Estimated Primary Completion Date : September 2021
Estimated Study Completion Date : January 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Arm Intervention/treatment
Experimental: NSCLC High PD-L1 Expressing
All Non-small cell lung cancer histologies with a high expression of PD-L1 as defined as TPS greater or equal to 50%. Treated with combination of niraparib and PD-1 Inhibitor.
Drug: Niraparib
PARP inhibitor, Capsule, 200mg dose, QD
Other Name: Zejula

Biological: PD-1 Inhibitor
Monoclonal antibody, IV administration

Experimental: NSCLC Low PD-L1 Expressing
All Non-small cell lung cancer histologies with a low expression of PD-L1 as defined as TPS 1-49%. Treated with combination of niraparib and PD-1 Inhibitor.
Drug: Niraparib
PARP inhibitor, Capsule, 200mg dose, QD
Other Name: Zejula

Biological: PD-1 Inhibitor
Monoclonal antibody, IV administration




Primary Outcome Measures :
  1. Objective Response Rate in patients with NSCLC whose tumors have high PD-L1 expression (Tumor Proportion Score >= 50%) [ Time Frame: Stage 1 6-8 months ]
    Proportion of patients with the confirmed overall response of complete response or partial response

  2. Objective Response Rate in patients with NSCLC whose tumors express PD-L1 (Tumor Proportion Score 1-49%) [ Time Frame: Stage 1 6-8 months ]
    Proportion of patients with the confirmed overall response of complete response or partial response


Secondary Outcome Measures :
  1. Treatment emergent adverse events, serious adverse events, assessment of clinical laboratory values [ Time Frame: Stage 1 6-8 months ]
    Assessed by CTCAE v4.03

  2. Duration of response [ Time Frame: Stage 1 6-8 months ]
    Time from first documented complete response or partial response until the subsequent documented disease progression or death

  3. Overall survival [ Time Frame: Stage 1 6-8 months ]
    Time from date of first dose to date of death

  4. Disease control rate [ Time Frame: Stage 1 6-8 months ]
    Proportion of patients with best overall response of complete response, partial response, or stable disease

  5. Progression free survival [ Time Frame: Stage 1 6-8 months ]
    Time from date of first dose to date of disease progression or death

  6. Pharmacokinetic parameter: area under the curve of niraparib [ Time Frame: Stage 1 6-8 months ]
  7. Pharmacokinetic parameter: maximum concentration of niraparib [ Time Frame: Stage 1 6-8 months ]
  8. Pharmacokinetic parameter: maximum concentration at steady state of niraparib [ Time Frame: Stage 1 6-8 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

General Inclusion Criteria:

  1. Male or female at least 18 years of age
  2. Histological or cytological proven advanced (unresectable) or metastatic NSCLC as defined as stage IIIB (positive supraclavicular lymph nodes) not amenable to definitive chemoradiotherapy or stage IV NSCLC
  3. Measurable disease by RECIST v1.1
  4. ECOG performance status of 0 to 1
  5. Adequate organ function, defined as (Note: CBC test should be obtained without transfusion or receipt of colony stimulating factors within 2 weeks before obtaining sample):

    1. Absolute neutrophil count (ANC) ≥ 1500/µL
    2. Platelets ≥ 100,000/µL
    3. Hemoglobin ≥ 9 g/dL or ≥ 5.6 mmol/L
    4. Serum creatinine ≤ 1.5 × upper limit of normal (ULN) or calculated creatinine clearance ≥ 50 mL/min using Cockcroft-Gault equation for patients with creatinine levels > 1.5× institutional ULN
    5. Total bilirubin ≤ 1.5 × ULN except in patients with Gilbert's syndrome. Patients with Gilbert's syndrome may enroll if direct bilirubin ≤ 1.5 × ULN of the direct bilirubin.
    6. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN unless liver metastases are present, in which case they must be ≤ 5× ULN
  6. Patient must have recovered to Grade 1 toxicity from prior cancer therapy (a patient with Grade 2 neuropathy or Grade 2 alopecia is an exception to this criterion and may qualify for this study).
  7. Provision of (archival or fresh) FFPE tumor tissue.
  8. Able to take oral medications
  9. Female patient has a negative serum pregnancy test within 72 hours prior to taking study drug if of childbearing potential, and agrees to abstain from activities that could result in pregnancy from enrollment through 120 days after the last dose of study treatment, or be of non-childbearing potential.
  10. Male patient agrees to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy.
  11. Able to understand the study procedures and agree to participate in the study by providing written informed consent

Cohort Specific Inclusion Criteria:

  1. Cohorts 1 and 1A (combination of niraparib and PD-1 inhibitor): patients must have tumors with high PD-L1 expression (TPS ≥ 50%) per local assessment; with no known EGFR-sensitizing mutation and/or ROS-1 or ALK translocations, and no prior systemic chemotherapy or PD-1/PD-L1 inhibitor treatment for metastatic NSCLC
  2. Cohorts 2 and 2A (combination of niraparib and PD-1 inhibitor): patients must have tumors with PD-L1 expression (TPS between 1% and 49%) per local assessment, with no known EGFR-sensitizing mutation and/or ROS-1 or ALK translocation, and no prior systemic chemotherapy or PD-1/PD-L1 inhibitor treatment for metastatic NSCLC

Cohorts 1, 1A, 2 and 2A Exclusion Criteria:

  1. Has received systemic therapy for the treatment of advanced stage NSCLC. Completion of treatment with chemotherapy and/or radiation as part of neoadjuvant/adjuvant therapy is allowed as long as therapy was completed at least 6 months prior to the diagnosis of metastatic disease
  2. Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
  3. Known hypersensitivity to the components of niraparib, PD-1 inhibitor, or their excipients
  4. Known EGFR (exon 19 and 21) mutations, ALK translocations, and/or ROS-1 translocations
  5. Condition (such as transfusion dependent anemia or thrombocytopenia), therapy, or laboratory abnormality that might confound the study results, or interfere with the patient's participation for the full duration of the study treatment.
  6. Known diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment
  7. Immunocompromised patient (Note: patients with splenectomy are allowed)
  8. Current participation in a treatment study or past participation in a study of an investigational agent within 4 weeks before the first dose of study treatment
  9. Symptomatic uncontrolled brain or leptomeningeal metastases
  10. Active autoimmune disease that required systemic treatment in the past 2 years (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment
  11. Major surgery within 3 weeks of starting the study or patient has not recovered from any effects of any major surgery
  12. Other active concomitant malignancy that warrants systemic therapy
  13. Poor medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, uncontrolled hypertension, or any psychiatric disorder that prohibits obtaining informed consent
  14. Known interstitial lung disease, drug-related pneumonitis, or radiation pneumonitis requiring steroid treatment
  15. Patient is pregnant, breastfeeding, or expecting to conceive children while receiving study treatment and for 180 days (for pregnancy or conception) or 30 days (for breastfeeding) after the last dose of study treatment
  16. Male patient is expecting to donate sperm or father children while receiving study drug or for 120 days after the last dose of study treatment
  17. Known active hepatic disease (known hepatic cirrhosis, hepatitis B surface antigen positive status, or suspected active hepatitis C infection)
  18. Prior treatment with a known poly (ADP-ribose) polymerase (PARP) inhibitor
  19. Patient who received a live vaccine within 30 days of planned start of study therapy
  20. Known history of MDS or AML

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03308942


Locations
Layout table for location information
United States, California
Innovative Clinical Research Institute
Whittier, California, United States, 90603
United States, Florida
Sylvester Comprehensive Cancer Center at U. of Miami
Miami, Florida, United States, 33136
Hematology Oncology Assoc of the Treasure Coast
Port Saint Lucie, Florida, United States, 34952
United States, Georgia
Emory University - Winship Cancer Institute
Atlanta, Georgia, United States, 30322
United States, Illinois
Ingalls Memorial Hospital
Harvey, Illinois, United States, 60426
Healthcare Research Network III
Tinley Park, Illinois, United States, 60487
United States, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02115
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215
United States, New York
Roswell Park Cancer Institute
Buffalo, New York, United States, 14263
United States, Ohio
University Hospitals Case Medical Center
Cleveland, Ohio, United States, 44106
United States, Tennessee
Tennessee Oncology
Nashville, Tennessee, United States, 37203
United States, Washington
Kadlec Clinic Hematology and Oncology
Kennewick, Washington, United States, 99336
Nortwest Medical Specialists
Tacoma, Washington, United States, 98405
Sponsors and Collaborators
Tesaro, Inc.
Covance
Myriad Genetics, Inc.
NeoGenomics Laboratories
DrugDev
Resolution Bioscience
Syneos Health
Almac Group
imedidata
Investigators
Layout table for investigator information
Study Director: Iryna Teslenko, M.D. Tesaro Inc., a GSK Company

Layout table for additonal information
Responsible Party: Tesaro, Inc.
ClinicalTrials.gov Identifier: NCT03308942     History of Changes
Other Study ID Numbers: 3000-02-001
First Posted: October 13, 2017    Key Record Dates
Last Update Posted: October 28, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Tesaro, Inc.:
Niraparib
Zejula
PARP Inhibitor
PD-1 Inhibitor
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Niraparib
Poly(ADP-ribose) Polymerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents